Brighthouse Financial (BHF) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
2024 saw strong execution of strategic initiatives, robust liquidity, and record sales in key product lines, but statutory results were below expectations due to new business growth strain and hedging complexity.
The company maintained a strong capital position, repurchased $250 million in stock, and reduced shares outstanding by 8% over 2023.
Strategic initiatives included reinsurance transactions, simplification of hedging strategies, and a focus on capital efficiency.
Expense discipline continued, with corporate expenses down over 7% from 2023.
Voting matters and shareholder proposals
Election of nine directors for one-year terms.
Ratification of Deloitte & Touche LLP as independent auditor for 2025.
Advisory vote on executive compensation (Say-on-Pay).
Approval of the amended and restated 2017 Stock and Incentive Compensation Plan.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of nine directors with diverse skills in leadership, insurance, financial services, IT/cybersecurity, and risk management.
Eight of nine directors are independent; all committees except Executive are composed solely of independent directors.
Annual director elections, majority voting standard, and no poison pill.
Regular board refreshment, annual self-assessments, and mandatory retirement at age 72.
Robust stockholder engagement program, with feedback influencing governance and compensation practices.
Latest events from Brighthouse Financial
- Q4 net income declined, but record annuity and life sales and a pending $4.1B acquisition marked 2025.BHF
Q4 202523 Feb 2026 - Merger and related proposals were approved by stockholders as recommended by the board.BHF
EGM 202612 Feb 2026 - Shareholders to vote on merger amid litigation and board's unanimous support.BHF
Proxy Filing4 Feb 2026 - Adjusted earnings reached $346M with record life sales, but statutory capital and RBC ratio declined.BHF
Q2 20242 Feb 2026 - Adjusted earnings surged on actuarial gains, with life sales up 19% and capital actions ongoing.BHF
Q3 202415 Jan 2026 - Shareholders to vote on $70/share cash merger with Aquarian Holdings; board recommends approval.BHF
Proxy Filing7 Jan 2026 - Q4 2024 net income was $646M, with record annuity and life sales and strong capital metrics.BHF
Q4 202426 Dec 2025 - Shareholders to vote on $70.00 per share cash merger, with board unanimous in recommending approval.BHF
Proxy Filing23 Dec 2025 - Preliminary proxy outlines annual meeting proposals and board governance for shareholder vote.BHF
Proxy Filing1 Dec 2025